The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
28
12
2023
received:
04
12
2023
accepted:
01
01
2024
pubmed:
31
1
2024
medline:
31
1
2024
entrez:
31
1
2024
Statut:
ppublish
Résumé
Prognostic impact of non-MPN driver gene mutations in primary myelofibrosis. MIPSS70: Mutation-Enhanced International Prognostic Score System.
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-758Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310-318.
Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769-1770.
Paz DL, Riou J, Verger E, et al. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv. 2021;5(5):1442-1451.
Guglielmelli P, Coltro G, Mannelli F, et al. ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Blood Adv. 2022;6(9):2927-2931.
Loscocco GG, Rotunno G, Mannelli F, et al. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. Am J Hematol. 2024;99(1):68-78.
Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869.